Curis, Inc. (NASDAQ:CRIS) has been given an average recommendation of “Hold” by the six analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $6.50.

CRIS has been the subject of several analyst reports. Guggenheim initiated coverage on Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 target price for the company. Zacks Investment Research upgraded Curis from a “sell” rating to a “hold” rating in a report on Monday, October 16th. ValuEngine upgraded Curis from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub upgraded Curis from a “strong sell” rating to a “sell” rating in a report on Thursday, August 17th.

In other Curis news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the acquisition, the chief executive officer now owns 115,890 shares in the company, valued at approximately $122,843.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.07% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its holdings in Curis by 58.7% in the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock worth $101,000 after buying an additional 13,448 shares during the period. OxFORD Asset Management LLP purchased a new stake in Curis in the 2nd quarter worth approximately $115,000. FNY Partners Fund LP lifted its holdings in Curis by 350.0% in the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after buying an additional 52,500 shares during the period. Voya Investment Management LLC lifted its holdings in Curis by 21.8% in the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after buying an additional 12,207 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in Curis by 338.7% in the 2nd quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock worth $158,000 after buying an additional 64,700 shares during the period. Institutional investors and hedge funds own 55.22% of the company’s stock.

Shares of Curis (NASDAQ:CRIS) opened at $0.80 on Friday. Curis has a fifty-two week low of $0.79 and a fifty-two week high of $3.48. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The company’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.21) earnings per share. equities research analysts anticipate that Curis will post -0.41 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/curis-inc-cris-receives-consensus-recommendation-of-hold-from-brokerages/1764753.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with Analyst Ratings Network's FREE daily email newsletter.